AKBA: Akebia Therapeutics, Inc. Company Aggregate Debts

Symbol and logo of brand Akebia Therapeutics Inc (AKBA)

Akebia Therapeutics (AKBA) develops comprehensive kidney therapy solutions, where high development costs and patent protection block new entrants. The price action history on GURU.Markets, which recorded the 0.21 metric, links these barriers to the creation of a treatment system that makes patients dependent on the brand's products. Simultaneously, the company is fighting for profitable market segments by displacing similar analogs.

AKBA: Akebia Therapeutics Company Debts 07/04/2022 - 11/01/2026

Akebia Therapeutics, Inc. (AKBA) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart Akebia Corp|AKBA - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Akebia|AKBA - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Akebia Therapeutics|AKBA - Company Book Value|Market Cap to Net Assets Ratio akebia.com|AKBA - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Akebia Therapeutics|AKBA - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Akebia Therapeutics Inc|AKBA - Company Debts|Debts to Book Capitalization Akebia|AKBA - Company Long-Term Debts|Short-Term Debt Volume Akebia Therapeutics|Immediate Liquidity Ratio akebia.com
- earnings and valuation multiples information:
AKBA - Company Net Income
Fundamental company analysis:AKBA Akebia Corp
Signature product of Akebia Therapeutics Inc

An investment audit of the issuer requires a detailed examination of the debt load before opening a position. This metric aggregates short-term and long-term liabilities, determining the business's overall financial dependence on borrowed capital. For Akebia Therapeutics (AKBA), this is critical when scaling sales of drugs for dialysis centers in the US. Debt service dynamics against a backdrop of growing demand determine the company's stability. The debt volume history clearly reflects this balance.

Competing companies

TVTX (Travere Corp) - Aggregate Debt Obligations|Company Aggregate Debts ARDX (Ardelyx, Inc.)|Company Aggregate Debts prokidney.com PROK|TVRD - Company Debts|Aggregate Debt Obligations DMAC (DiaMedica Therapeutics Inc)|Unicycive (UNCY) - Company Debts|Company Total Debt rockwellmed.com|CVKD (Cadrenal Therapeutics) - Company Aggregate Debts|Company Aggregate Debts conduitpharma.com|Company Total Debt CALT (Calliditas Therapeutics)|RNLX (Renalytix Plc) - Aggregate Debt Obligations|Company Debts ZyVersa Therapeutics, Inc. ZVSA